- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/02 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
Patent holdings for IPC class C07D 239/02
Total number of patents in this class: 297
10-year publication summary
|
9
|
5
|
10
|
1
|
8
|
6
|
2
|
3
|
5
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3728 |
16 |
| Novartis AG | 10331 |
11 |
| Boehringer Ingelheim International GmbH | 4486 |
10 |
| Rigel Pharmaceuticals, Inc. | 508 |
8 |
| Janssen Pharmaceutica N.V. | 3189 |
7 |
| Corteva Agriscience LLC | 2650 |
7 |
| Bristol-myers Squibb Company | 4755 |
6 |
| Merck Sharp & Dohme Corp. | 2183 |
6 |
| Abbvie Inc. | 1838 |
6 |
| Hoffmann-La Roche Inc. | 3743 |
4 |
| Alexion Pharmaceuticals, Inc. | 642 |
4 |
| Gilead Sciences, Inc. | 2212 |
4 |
| Genentech, Inc. | 4096 |
3 |
| Amgen Inc. | 4399 |
3 |
| DSM IP Assets B.V. | 5418 |
3 |
| Takeda Pharmaceutical Company Limited | 2714 |
3 |
| Emory University | 1716 |
3 |
| The Salk Institute for Biological Studies | 450 |
3 |
| The Scripps Research Institute | 1341 |
3 |
| Innovation Pharmaceuticals Inc. | 16 |
3 |
| Other owners | 184 |